Pfizer, PhRMA See Signs Of Drug Approval "Slowdown" At FDA

Pfizer believes that several of its pending products have been delayed by an "across-the-board" slowdown in FDA approvals, CEO Henry McKinnell told investors during the company's Jan. 24 quarterly conference call.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet